We are live on ! Find out more
EBS icon

Emergent Biosolutions

291 hedge funds and large institutions have $2.82B invested in Emergent Biosolutions in 2021 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 110 increasing their positions, 108 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 108

0.17% less ownership

Funds ownership: 83.74% → 83.57% (-0.17%)

12% less capital inflows, than outflows

Capital inflows: $410M | Capital outflows: $469M

14% less funds holding

Funds holding: 340 → 291 (-49)

28% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $15.8M

59% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 83

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

Holders
291
Holders Change
-49
Holders Change %
-14.41%
% of All Funds
5.04%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
34
Increased
110
Reduced
108
Closed
83
Calls
$11.4M
Puts
$15.8M
Net Calls
-$4.34M
Net Calls Change
-$4.31M

EBS Hedge Fund Activity: Q2 2021 in Review

291 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2021, worth a combined $2.82B — down 32% from $4.14B a quarter earlier.

Sellers outnumbered buyers: 83 funds closed out of EBS and 34 opened new positions — a net loss of 49 holders — while 108 trimmed existing stakes and 110 added.

The largest buyer was Janus Henderson Group, adding an estimated $57.1M. The largest seller was Fuller & Thaler Asset Management, exiting entirely with an estimated $46.8M sold.

  • 291 institutional investors held Emergent Biosolutions (EBS) as of Q2 2021, down from 340 in Q1 2021.
  • Funds reported $2.82B of Emergent Biosolutions stock for Q2 2021, down 32% quarter-over-quarter.
  • 34 funds opened new Emergent Biosolutions positions in Q2 2021 and 83 closed out, a net change of -49 holders.
  • The largest Emergent Biosolutions buyer in Q2 2021 was Janus Henderson Group, an estimated $57.1M added.
  • The largest Emergent Biosolutions seller in Q2 2021 was Fuller & Thaler Asset Management, an estimated $46.8M sold.

Based on aggregated 13F filings for Q2 2021.